The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Cardiorespiratory complications are the predominant source of morbidity in patients undergoing major surgery.

The aim of this study was to assess the effects of perioperative rhGH on cardiac function in 33 patients undergoing elective infrarenal abdominal aortic aneurysm repair.

Who Took Part

The abstract describes 33 patients taking part.

The age groups tagged for this paper are older adults, both men and women.

Patients were assessed on days 7 and 1 before and days 7, 14 and 50 after operation.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

PubMed files the paper under topics including Aortic Aneurysm, Abdominal, Cardiac Output, Elective Surgical Procedures, Hemodynamics, Human Growth Hormone, Intraoperative Complications and Monitoring, Intraoperative.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 33 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.